Aldeyra Therapeutics Reveals Results from ADX-102 Trial

Aldeyra Therapeutics (NASDAQ:ALDX) presented the results from their Phase 2 clinical trial of ADX-102 at this years’ meeting of the Association for Research in Vision and Ophthalmology.
As quoted in the press release:

Data from the trial demonstrated ADX-102 activity comparable to standard-of-care topical ocular corticosteroids in reducing anterior chamber cell count in patients with active noninfectious anterior uveitis (NAU). Unlike corticosteroid therapy, ADX-102 did not increase intraocular pressure, a major corticosteroid side effect that can lead to glaucoma, a potentially blinding chronic condition. Dr. John Sheppard, an internationally recognized expert in ocular inflammation, gave the presentation which is available on the investor relations page of the Aldeyra Therapeutics corporate website at ir.aldeyra.com.
“The need to reduce exposure to the deleterious side effects of corticosteroids are well known within the ophthalmology community,” commented Dr. John Sheppard. “The results of this important clinical trial suggest the potential therapeutic applicability of topical ocular ADX-102 as a novel and safe approach for the treatment of inflammation.”
Forty-five subjects were randomized equally to receive 0.5% ADX-102 four times daily, Pred Forte® (a corticosteroid) four times daily (tapered), or 0.5% ADX-102 four times daily and Pred Forte® twice daily (tapered). There were no statistical differences among all groups for the clinical endpoints, including anterior chamber cell count and ocular flare. ADX-102 was generally well tolerated and there were no serious adverse events, consistent with previous Phase 1 and Phase 2 clinical trials.

Click here to read the full press release.

Source: www.marketwired.com